Video Shorts

Most Popular

Popular in No name

Breast Cancer3m 2s
ESR1 Mutation as an emerging clinical biomarker metastatic hormone receptor positive Breast Cancer
Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.
biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd
Watch Now
Multiple Myeloma3m 16s
Need of Geriatric assessment in Multiple Myeloma
Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.
geriatric assessment multiple myeloma quality of life
Watch Now
OncoSpecials2m 41s
Low Dose Dasatinib Ready For Clinical Practice
Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.
low dose dasatinib dasatinib 50mg
Watch Now
Breast Cancer1m 21s
Recent advances in triple-negative breast cancer (TNBC)
Metastatic Triple Negative Breast Cancer is still an unmet medical need.
germline brca mutation pdl1 triple negative breast cancer
Watch Now
Oncology3m 36s
Tissue Agnostic Treatment options in Solid Tumors
Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.
personalized medicine precision medicine tissue agnostic treatment
Watch Now
Prostate Cancer3m 41s
Whole genome sequencing in clinical practice
Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration
precision medicine prostate cancer whole genome sequencing
Watch Now
Breast Cancer2m 3s
Immunotherapy in Breast Cancer : Where Are We ?
Immunotherapy has redefined the treatment of Triple Negative Breast Cancer.
immunotherapy metastatic triple negative breast cancer
Watch Now
Multiple Myeloma3m 12s
Tips for Optimising Long Term Lenalidomide Maintenance in Multiple Myeloma
Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.
long term maintenance therapy lenalidomide tips
Watch Now
Myelodysplastic Syndromes4m 34s
Practical Approach for Using Iron Chelation Therapy in MDS
Iron chelation therapy (ICT) in MDS is used to manage iron overload from frequent blood transfusions. It involves identifying patients who would benefit most, monitoring iron levels, and managing side effects of chelators
iron chelation therapy (ict) iron overload risk reduction improved qol
Watch Now
Myelodysplastic Syndromes2m 31s
Duration of treatment does it improve outcomes Hypomethylating agents in MD
Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
duration of treatment hypomethylating agents mds
Watch Now